OACC · Oaktree Acquisition Corp. III Life Sciences - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | - | - | - | - | - |
| Total Operating Expenses | $456.5K | - | $48.1K | $269.8K | $444.8K |
| D&A | - | - | - | - | - |
| Operating Income | ($456.5K) | - | ($48.1K) | ($269.8K) | ($444.8K) |
| Interest Expense | - | - | - | - | - |
| Income Tax | - | - | - | - | - |
| Net Income | $1.39M | - | ($48.1K) | $1.87M | $1.66M |
| EPS - Basic | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.28M | $1.43M | $1.33M | $1.39M | $1.36M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - |
| Current Assets | $1.42M | $1.55M | $1.48M | $1.56M | $1.56M |
| Total Assets | $204.83M | $203.11M | $201.25M | $199.18M | $195.25M |
| Current Liabilities | $1.62M | $1.30M | $1.23M | $1.12M | $727.3K |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $8.64M | $8.32M | $8.25M | $8.14M | $7.75M |
| Stockholders' Equity | ($7.23M) | ($6.77M) | ($23.1K) | ($6.54M) | ($6.52M) |
| Retained Earnings | ($7.23M) | ($6.77M) | ($6.77M) | ($6.54M) | ($6.08M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($158.0K) | - | $0 | - | ($75.6K) |
| Investing Cash Flow | - | - | $0 | - | - |
| Financing Cash Flow | - | - | - | - | - |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | 0.7% | - | -0.0% | 0.9% | 0.8% |
| Return on equity | -19.3% | - | 208.2% | -28.7% | -25.4% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.87 | 1.19 | 1.21 | 1.39 | 2.14 |
| Quick ratio | 0.87 | 1.19 | 1.21 | 1.39 | 2.14 |
| Cash ratio | 0.79 | 1.10 | 1.08 | 1.24 | 1.87 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -28.34 | -30.00 | -8714.01 | -30.46 | -29.95 |
| Liabilities / Assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -2.6% | - | - | - | - |
| Net income growth (YoY) | -16.0% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -10.9% | - | - | - | - |
Peer comparison
Same SIC group: Blank Checks
Comparing Oaktree Acquisition Corp. III Life Sciences against the 5 most active filers in the same SIC group.